Angiogenesis Inhibitors

"Angiogenesis Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.

Descriptor ID	D020533
MeSH Number(s)	D27.505.696.377.077.099 D27.505.696.377.450.100 D27.505.954.248.025
Concept/Terms	Angiogenesis Inhibitors Angiogenesis Inhibitors Neovascularization Inhibitors Angiogenic Antagonists Angiogenic Inhibitors Angiostatic Agents Agents, Angiostatic Antagonists, Angiogenic Anti-Angiogenetic Agents Agents, Anti-Angiogenetic Anti Angiogenetic Agents Anti-Angiogenic Drugs Anti Angiogenic Drugs Drugs, Anti-Angiogenic Antiangiogenic Agents Agents, Antiangiogenic Inhibitors, Angiogenesis Inhibitors, Angiogenetic Inhibitors, Angiogenic Inhibitors, Neovascularization Angiogenetic Antagonists Antagonists, Angiogenetic Angiogenetic Inhibitors Angiogenesis Factor Inhibitors Angiogenesis Factor Inhibitors Factor Inhibitors, Angiogenesis Inhibitors, Angiogenesis Factor Anti-Angiogenesis Effect Anti-Angiogenesis Effect Anti Angiogenesis Effect Effect, Anti-Angiogenesis Antiangiogenesis Effect Effect, Antiangiogenesis Antiangiogenesis Effects Effects, Antiangiogenesis Anti-Angiogenesis Effects Anti Angiogenesis Effects Effects, Anti-Angiogenesis

Below are MeSH descriptors whose meaning is more general than "Angiogenesis Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Physiological Effects of Drugs [D27.505.696]
Growth Substances [D27.505.696.377]
Angiogenesis Modulating Agents [D27.505.696.377.077]
Angiogenesis Inhibitors [D27.505.696.377.077.099]
Growth Inhibitors [D27.505.696.377.450]
Angiogenesis Inhibitors [D27.505.696.377.450.100]
Therapeutic Uses [D27.505.954]
Antineoplastic Agents [D27.505.954.248]
Angiogenesis Inhibitors [D27.505.954.248.025]

Below are MeSH descriptors whose meaning is related to "Angiogenesis Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Angiogenesis Inhibitors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Angiogenesis Inhibitors" by people in this website by year, and whether "Angiogenesis Inhibitors" was a major or minor topic of these publications.

Bar chart showing 67 publications over 20 distinct years, with a maximum of 9 publications in 2015

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2001	0	1	1
2004	3	1	4
2005	1	0	1
2006	1	0	1
2008	3	1	4
2009	2	1	3
2010	1	0	1
2011	3	1	4
2012	3	1	4
2013	1	0	1
2014	6	1	7
2015	7	2	9
2016	4	3	7
2017	0	1	1
2018	1	0	1
2019	0	2	2
2021	1	6	7
2022	0	5	5
2023	0	2	2
2024	0	2	2

Below are the most recent publications written about "Angiogenesis Inhibitors" by people in Profiles.

Mita MM, Mita AC, Carver BJ, Shanahan JM, Mayes BA, Dufour PJ, Browning D, Anderson-Villaluz A, Petersen JS, Turnquist DJ, Cornelius P. A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2. Cancer Res Commun. 2025 Jun 01; 5(6):1008-1017.

View in: PubMed
Lam A, Gulati S, Foster BS, Lally DR. CENTRAL RETINAL VEIN OCCLUSION ASSOCIATED WITH USE OF AMYL NITRITE "POPPERS". Retin Cases Brief Rep. 2024 Jan 01; 18(1):138-140.

View in: PubMed
Bowe T, Mahmoudzadeh R, Soares RR, Nguyen MK, Hsu J, Kuriyan AE. CHARACTERISTICS OF PARTICIPANTS IN DIABETIC RETINOPATHY CLINICAL RESEARCH CLINICAL TRIALS WHO WERE LOST TO FOLLOW-UP. Retina. 2024 01 01; 44(1):111-116.

View in: PubMed
Archambault SD, Nichols MM, McCullum JC, Zhang Y, Steinberger EE, Ramsey DJ. Patient adherence to therapy after switch to aflibercept from bevacizumab or ranibizumab for treatment-refractory neovascular age-related macular degeneration. Indian J Ophthalmol. 2024 01 01; 72(Suppl 1):S101-S105.

View in: PubMed
Akkan Aydogmus FS, Onwuka O, Saddemi J, Lasalle CC, Ramsey DJ. Second eyes to develop neovascular age-related macular degeneration have fewer symptoms and better one-year visual outcomes. BMC Ophthalmol. 2023 Jul 07; 23(1):303.

View in: PubMed
Samuelson AG, Nahar A, Patel SN, Mahmoudzadeh R, Salabati M, Yu-Chuan Kang E, Hinkle JW, Soares RR, Kuriyan AE, Garg SJ. CLINICAL OUTCOMES OF PATIENTS WITH ENDOPHTHALMITIS AFTER DEXAMETHASONE INTRAVITREAL IMPLANT. Retina. 2022 10 01; 42(10):1915-1920.

View in: PubMed
Santoni M, Molina-Cerrillo J, Myint ZW, Massari F, Buchler T, Buti S, Matrana MR, De Giorgi U, Rizzo M, Zabalza IO, Galli L, Zucali PA, Aurilio G, Incorvaia L, Bassanelli M, Mammone G, Salfi A, Isella L, Mollica V, Grande E, Porta C, Battelli N. Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies. Target Oncol. 2022 09; 17(5):571-581.

View in: PubMed
Patel SN, Mokhashi N, Peck TJ, Cai LZ, Salabati M, Soares RR, Hinkle J, Chaudhary V, Kuriyan AE, Cohen MN, Hsu J, Garg SJ. Seasonal and Environmental Variations in Endophthalmitis after Intravitreal Anti-vascular Endothelial Growth Factor Injection: A Six-year Review. Curr Eye Res. 2022 09; 47(9):1288-1293.

View in: PubMed
Lally DR, Hill L, Amador-Patarroyo MJ. Subretinal Fluid Resolution and Visual Acuity in Patients with Neovascular Age-Related Macular Degeneration: A HARBOR Post Hoc Analysis. Ophthalmol Retina. 2022 11; 6(11):1054-1060.

View in: PubMed
Lally DR, Loewenstein A, Arnold JJ, Yang YC, Gedif K, Best C, Patel H, Tadayoni R, Heier JS. Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies. Eye (Lond). 2023 04; 37(6):1242-1248.

View in: PubMed

People

Explore

Similar Concepts

Top Journals